My Application Form Status

Check the status of your application form with Angel Broking.
  • Companies
  • Everything else
Search
Gokaldas Exports declines as Blackstone offloads bulk shares
Jul 21,2016

Meanwhile, the S&P BSE Sensex was down 22.34 points or 0.08% at 27,893.55.

On BSE, so far 66,000 shares were traded in the counter as against average daily volume of 2.35 lakh shares in the past one quarter. The stock hit a high of Rs 111.70 and a low of Rs 105.40 so far during the day. The stock had hit a 52-week low of Rs 40.45 on 12 February 2016. The stock had hit a 52-week high of Rs 134.20 on 10 June 2016. The stock had underperformed the market over the past one month till 20 July 2016, advancing 0.5% compared with Sensexs 3.9% rise. The scrip had, however, outperformed the market in past one quarter, gaining 52.51% as against Sensexs 8.02% rise.

The small-cap company has equity capital of Rs 17.44 crore. Face value per share is Rs 5.

Gokaldas Exports net profit rose 17% to Rs 40.77 crore on 23.2% growth in net sales to Rs 292.52 crore in Q4 March 2016 over Q4 March 2015.

Gokaldas Exports manufactures and exports readymade garments.

Powered by Capital Market - Live News

Hindustan Zinc drops after reporting weak Q1 results
Jul 21,2016

The result was announced after market hours yesterday, 20 July 2016.

Meanwhile, the BSE Sensex was up 31.50 points, or 0.11%, to 27,940.51.

On BSE, so far 32,346 shares were traded in the counter, compared with an average volume of 1.23 lakh shares in the past one quarter. The stock hit a high of Rs 192.45 and a low of Rs 187.95 so far during the day.

The large-cap company has an equity capital of Rs 845.06 crore. Face value per share is Rs 2.

Hindustan Zinc said that the decrease in revenues was on account of lower volumes, primarily zinc, and lower LME prices partly offset by higher rupee depreciation and higher silver price. The zinc metal cost of production per metric tonne before royalty (COP) in Q1 June 2016 increased Rs 62138 in line with production plan of lower volumes from Rampura Agucha open cast mine in the current quarter and thus lower average grades. This was partly offset by lower coal & commodity prices, cost optimization projects in procurement & commercial and higher by-product credits. The COP indollar terms will be better in the year ending 31 March 2017 (FY 2017) compared to previous year. The fall in revenue and rise in cost of production resulted in a 33% decline in earnings before interest, taxes, depreciation and amortization (EBITDA) to Rs 1130 crore in Q1 June 2016 over Q1 June 2015.

The smaller investment corpus on account of dividend pay-out in the beginning of the quarter led to lower investment income, which along with higher tax rate and higher depreciation resulted in fall in net profit.

Mr. Agnivesh Agarwal, Chairman of Hindustan Zinc said that in line with strong zinc fundamentals and companys expectations, zinc prices surged 14% in Q1 June 2016 over Q1 June 2015, making it the best performing base metal. The company also witnessed a rally in silver prices, which along with increasing volumes is accentuating its contribution to profits, havingreached almost 20% at present. The transition to underground mining is progressing well with robust mine development, especially during last few months. Production from underground mines has also ramped up significantly, he added.

Hindustan Zinc is a subsidiary of Vedanta (formerly known as Sesa Sterlite), a part of London listed Vedanta Resources plc, a global diversified natural resources company. The company is one of the largest integrated producers of zinc-lead and a leading producer of silver. As per the shareholding pattern, Vedanta holds 64.92% stake and the Government of India holds 29.54% stake in Hindustan Zinc as at 30 June 2016.

Powered by Capital Market - Live News

New export order boosts SSWL
Jul 20,2016

The announcement was made during market hours today, 20 July 2016.

Meanwhile, the S&P BSE Sensex was up 122.49 points or 0.44% at 27,910.11.

On BSE, so far 14,000 shares were traded in the counter as against average daily volume of 9,131 shares in the past one quarter. The stock hit a high of Rs 488 and a low of Rs 469 so far during the day. The stock had hit a record high of Rs 495 on 15 July 2016. The stock had hit a 52-week low of Rs 284 on 17 February 2016. The stock had outperformed the market over the past one month till 19 July 2016, advancing 7.26% compared with Sensexs 4.36% rise. The scrip had also outperformed the market in past one quarter, gaining 22.39% as against Sensexs 7.64% rise.

The small-cap company has equity capital of Rs 15.52 crore. Face value per share is Rs 10.

Steel Strips Wheels (SSWL) said it has secured its maiden export order from Mobius Motors, Kenya. Supplies would be executed from the companys Dappar plant in Punjab. SSWL, which is already supplying wheels to Morocco and Egypt, aims to further increase its presence in the African continent. Recent order from Kenya supports this strategy, SSWL said.

SSWLs net profit rose 55.1% to Rs 18.49 crore on 5.1% growth in net sales to Rs 308.88 crore in Q4 March 2016 over Q4 March 2015.

SSWL designs & manufactures automotive steel wheels and is among the leading supplier to Indian & global automobile manufacturers.

Powered by Capital Market - Live News

Bhel gains after commissioning a unit of power project
Jul 20,2016

The announcement was made during market hours today, 20 July 2016.

Meanwhile, the S&P BSE Sensex was up 122.71 points or 0.44% at 27,910.33.

On BSE, so far 6.1 lakh shares were traded in the counter as against average daily volume of 8.24 lakh shares in the past one quarter. The stock hit a high of Rs 143.45 and a low of Rs 139.65 so far during the day. The stock had hit a 52-week high of Rs 289.85 on 21 July 2015. The stock had hit a 52-week low of Rs 90.40 on 29 February 2016. The stock had outperformed the market over the past one month till 19 July 2016, advancing 14.06% compared with Sensexs 4.36% rise. The scrip had, however, underperformed the market in past one quarter, gaining 5.4% as against Sensexs 7.64% rise.

The large-cap company has equity capital of Rs 489.52 crore. Face value per share is Rs 2.

Bharat Heavy Electricals (Bhel) has successfully commissioned the third unit of the 160 megawatts (MW) Teesta Low Dam Hydro Electric Project (HEP) Stage-IV in West Bengal. The greenfield project located in Darjeeling district of West Bengal, Teesta HEP is being set up by National Hydroelectric Power Corporation (NHPC), on the River Teesta. The fourth and final unit of the project is also in advanced stages of execution. The order for electrical & mechanical (E&M) works for four units of 40 MW each was placed on Bhel by NHPC.

Bhel is presently executing hydro electric projects of around 3,300 MW in the country which are under various stage of implementation. Other projects of NHPC currently under execution by Bhel are the 800 MW Parbati HEP Stage - II and 330 MW Kishanganga HEP. In West Bengal, Bhel is also executing the 120 MW Rammam Stage-III hydro-electric project of NTPC. Significantly, more than 500 hydro generating sets with a cumulative capacity of more than 29,000 MW of various ratings have been contracted on Bhel in India and abroad. Of this, equipment for about 5,700 MW generating capacity has been contracted outside India.

Bhels net profit fell 59.5% to Rs 359.58 crore on 20.8% fall in net sales to Rs 9792.04 crore in Q4 March 2016 over Q4 March 2015.

State-run Bharat Heavy Electricals (Bhel) is an integrated power plant equipment manufacturer. It is one of the largest engineering and manufacturing companies in India engaged in the design, engineering, manufacture, construction, testing, commissioning and servicing of a wide range of products and services for core sectors of the economy, viz. power, transmission, industry, railways, renewable energy, oil & gas, water and defence. The Government of India currently holds 63.06% stake in Bhel (as per the shareholding pattern as on 30 June 2016)

Powered by Capital Market - Live News

ACC gains after commencing commercial production at clinker facility
Jul 20,2016

The announcement was made during market hours today, 20 July 2016.

Meanwhile, the S&P BSE Sensex was up 116.39 points or 0.42% at 27,904.01.

On BSE, so far 17,000 shares were traded in the counter as against average daily volume of 19,056 shares in the past one quarter. The stock hit a high of Rs 1,633.40 and a low of Rs 1,604 so far during the day. The stock had hit a 52-week high of Rs 1,640 on 15 July 2016. The stock had hit a 52-week low of Rs 1,173.25 on 29 February 2016. The stock had underperformed the market over the past one month till 19 July 2016, advancing 3.36% compared with Sensexs 4.36% rise. The scrip had, however, outperformed the market in past one quarter, gaining 9.51% as against Sensexs 7.64% rise.

The large-cap company has equity capital of Rs 187.79 crore. Face value per share is Rs 10.

ACC said that two new cement grinding facilities, one each at Jamul in Chhattisgarh and Sindri in Jharkhand, which form part of this integrated project, are expected to be commissioned within third quarter of 2016. This project will facilitate the company in serving its expanding customer base in the fast-growing market in East India, offering premium quality products like ACC F2R (Foundation to Roof), ACC Plus and Hi-performance PSC cements for complete concreting solutions, ACC said in a statement.

ACC is scheduled to announce its Q2 June 2016 results on 26 July 2016. The companys consolidated net profit fell 4.1% to Rs 226.95 crore on 1.5% growth in net sales to Rs 2927.38 crore in Q1 March 2016 over Q1 March 2015.

ACC is a manufacturer of cement and ready mixed concrete with a countrywide network of factories and sales offices.

Powered by Capital Market - Live News

Greenply Industries gains after incorporating step-down subsidiary in Africa
Jul 20,2016

The announcement was made during market hours today, 20 July 2016.

Meanwhile, the S&P BSE Sensex was up 104.17 points or 0.37% at 27,891.79.

On BSE, so far 12,543 shares were traded in the counter as against average daily volume of 12,049 shares in the past one quarter. The stock hit a high of Rs 274.30 and a low of Rs 264.20 so far during the day. The stock had hit a record high of Rs 297.50 on 15 July 2016. The stock had hit a 52-week low of Rs 152 on 18 January 2016. The stock had outperformed the market over the past one month till 19 July 2016, gaining 6.65% compared with Sensexs 4.36% rise. The scrip had also outperformed the market in past one quarter, gaining 36.41% as against Sensexs 7.64% rise.

The mid-cap company has equity capital of Rs 12.07 crore. Face value per share is Rs 1.

In May this year, Greenply Industries board of directors had approved incorporation of step-down subsidiary in Gabon to manage and control the veneer, lumber and panel products manufacturing unit at Nkok SEZ, Gabon, West Africa. The board had also approved to set up the unit in Gabon on that day.

Greenply Industries net profit fell 92.4% to Rs 1.08 crore on 5.7% growth in net sales to Rs 452.83 crore in Q4 March 2016 over Q4 March 2015.

Greenply Industries is into manufacturing and marketing of a wide range of interior infrastructure products.

Powered by Capital Market - Live News

Anant Raj hits 52-week high after boards nod for demerger proposals
Jul 20,2016

The announcement was made after market hours yesterday, 19 July 2016.

Meanwhile, the S&P BSE Sensex was up 76.76 points or 0.28% at 27,864.38.

The stock spurted on heavy volumes. On BSE, so far 20.73 lakh shares were traded in the counter as against average daily volume of 3.15 lakh shares in the past one quarter. The stock hit a high of Rs 55.70 so far during the day, which is a 52-week high for the counter. The stock hit a low of Rs 51.50 so far during the day. The stock had hit a 52-week low of Rs 27.55 on 26 February 2016. The stock had underperformed the market over the past one month till 19 July 2016, sliding 5.05% compared with Sensexs 4.36% rise. The scrip had, however, outperformed the market in past one quarter, gaining 31.06% as against Sensexs 7.64% rise.

The small-cap company has equity capital of Rs 59.02 crore. Face value per share is Rs 2.

Anant Rajs board approved demerger of real estate division of Anant Raj Agencies (ARAPL) into Tauras Promoters & Developers (TPDPL) and subsequent amalgamation of remaining ARAPL with the company. The Board also approved demerger of project division of the company into Anant Raj Global (ARGL) and subsequent listing of ARGL at Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE). These demerger schemes are subject to necessary approvals.

On consolidated basis, Anant Rajs net profit fell 27.9% to Rs 12.33 crore on 20% decline in net sales to Rs 116.23 crore in Q4 March 2016 over Q4 March 2015.

Anant Raj Group is one of the leading construction and infrastructure developers in North India.

Powered by Capital Market - Live News

Volumes jump at PI Industries counter
Jul 20,2016

PI Industries clocked volume of 4.21 lakh shares by 13:23 IST on BSE, a 54.72-times surge over two-week average daily volume of 8,000 shares. The stock fell 1.09% at Rs 727.65.

Bajaj Finserv notched up volume of 7.04 lakh shares, a 33.03-fold surge over two-week average daily volume of 21,000 shares. The stock rose 0.1% at Rs 2,499.30.

Info Edge (India) saw volume of 1.48 lakh shares, a 26.47-fold surge over two-week average daily volume of 6,000 shares. The stock was up 0.63% at Rs 827.55.

Page Industries clocked volume of 12,000 shares, a 14.23-fold surge over two-week average daily volume of 1,000 shares. The stock rose 1.4% at Rs 13,471.80.

Apollo Hospitals Enterprise saw volume of 1.27 lakh shares, a 13.84-fold rise over two-week average daily volume of 9,000 shares. The stock fell 0.86% at Rs 1,330.25.

Powered by Capital Market - Live News

63 moons hits 52-week low
Jul 20,2016

Meanwhile, the S&P BSE Sensex was up 75.79 points or 0.27% at 27,863.41.

On BSE, so far 7.96 lakh shares were traded in the counter as against average daily volume of 1.38 lakh shares in the past one quarter. The stock hit a low of Rs 70.20 so far during the day, which is a 52-week low for the counter. The stock hit a high of Rs 81.95 so far during the day. The stock had hit a 52-week high of Rs 169.60 on 6 August 2015. The stock had underperformed the market over the past one month till 19 July 2016, sliding 1.78% compared with Sensexs 4.36% rise. The scrip had also underperformed the market in past one quarter, declining 6.57% as against Sensexs 7.64% rise.

The small-cap company has equity capital of Rs 9.22 crore. Face value per share is Rs 2.

63 moons technologies (formerly Financial Technologies (India)) in a clarification issued to the stock exchanges after market hours yesterday, 19 July 2016 said that it has received a letter from the Economic Offences Wing (EOW) dated 18 July 2016, securing assets of the company. 63 moons said it will take all legal remedies to protect the interest of its shareholders and employees. There is no legal basis for the action from EOW and the company will be moving court soon on the letter from EOW, 63 moons said in a statement.

It may be recalled that the Enforcement Directorate, Mumbai had last week placed 63 moons technologies promoter Jignesh Shah under arrest.

63 moons technologies reported net loss of Rs 39.31 crore in Q4 March 2016, higher than net loss of Rs 5.66 crore in Q4 March 2015. Net sales declined 24.8% to Rs 31.62 crore in Q4 March 2016 over Q4 March 2015.

63 moons technologies is among the global leaders in offering technology IP (Intellectual Property) and domain expertise to create and trade on next generation financial markets. It is a global leader in creating and operating next-generation tech-centric financial exchanges.

Powered by Capital Market - Live News

Sun Pharma gains after receiving USFDA nod for generic drug
Jul 20,2016

The announcement was made during market hours today, 20 July 2016.

Meanwhile, the BSE Sensex was up 388.78 points, or 1.43%, to 27,515.68.

On BSE, so far 55,127 shares were traded in the counter, compared with average daily volume of 2.89 lakh shares in the past one quarter. The stock hit a high of Rs 789.60 and a low of Rs 782 so far during the day. The stock hit a 52-week high of Rs 965.15 on 20 August 2015. The stock hit a 52-week low of Rs 706.40 on 24 November 2015. The stock had outperformed the market over the past one month till 19 July 2016, gaining 5.3% compared with 4.36% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, dropping 6.52% as against Sensexs 7.64% rise.

The large-cap company has an equity capital of Rs 240.68 crore. Face value per share is Re 1.

Sun Pharmaceutical Industries announced that one of its subsidiaries received final approval from United States Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for generic version of Crestor, Rosuvastatin Calcium tablets 5 mg (base), 10 mg (base), 20 mg (base) and 40 mg (base).

Rosuvastatin Calcium tablets are therapeutic equivalents of IPR Pharmaceuticals, Inc.s Crestor tablets. As per IMS MAT May 2016 data, these tablets have annual sales of approximately $6.8 billion in the US. These tablets are indicated for the treatment of adult patients with Hypertriglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) and adult patients with Homozygous Familial Hypercholesterolemia.

Sun Pharmaceutical Industries (Sun Pharma) consolidated net profit rose 92.7% to Rs 1713.69 crore on 21.5% growth in net sales to Rs 7413.87 crore in Q4 March 2016 over Q4 March 2015.

Sun Pharmaceutical Industries is a specialty generic pharmaceutical company and Indias top pharmaceutical company.

Powered by Capital Market - Live News

Shree Cement retracts from record high
Jul 20,2016

The announcement was made after market hours yesterday, 19 July 2016.

Meanwhile, the S&P BSE Sensex was up 108.59 points or 0.39% at 27,896.21.

On BSE, so far 143 shares were traded in the counter as against average daily volume of 1,840 shares in the past one quarter. The stock was volatile. The stock rose as much as 1.44% at the days high of Rs 16,430 so far during the day, which is a record high for the counter. The stock lost as much as 0.09% at the days low of Rs 16,180 so far during the day. The stock had hit a 52-week low of Rs 9,350 on 15 January 2016. The stock had outperformed the market over the past one month till 19 July 2016, advancing 17.85% compared with Sensexs 4.36% rise. The scrip had also outperformed the market in past one quarter, gaining 24.73% as against Sensexs 7.64% rise.

The large-cap company has equity capital of Rs 34.84 crore. Face value per share is Rs 10.

Shree Cement had earlier informed that it had completed the up-gradation of preheater of clinker line of unit-I at Beawar (Rajasthan) on 15 July 2016.

Shree Cements net profit rose 86.5% to Rs 223.34 crore on 28.2% increase in net sales to Rs 2017.41 crore in Q3 March 2016 over Q3 March 2015.

Shree Cement is focused on its core business of cement and power. Currently its manufacturing operations are spread over North and Eastern India across five states.

Powered by Capital Market - Live News

DLF gains after realigning shareholding arrangement in JV companies
Jul 20,2016

The announcement was made before market hours today, 20 July 2016.

Meanwhile, the S&P BSE Sensex was up 89.35 points or 0.32% at 27,876.97.

On BSE, so far 2.59 lakh shares were traded in the counter as against average daily volume of 11.18 lakh shares in the past one quarter. The stock hit a high of Rs 154.85 and a low of Rs 152 so far during the day. The stock had hit a 52-week high of Rs 163.30 on 13 July 2016. The stock had hit record low of Rs 72.50 on 12 February 2016. The stock had outperformed the market over the past one month till 19 July 2016, gaining 13.13% compared with 4.36% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 21.73% as against Sensexs 7.64% rise.

The large-cap company has equity capital of Rs 356.75 crore. Face value per share is Rs 2.

DLF said that it has been jointly decided by DLF and Ridgewood Holdings to realign the current shareholding arrangement in the joint venture companies in order to maintain continued focus of future development of various projects. The decision was taken as given the current strategy coupled with market conditions DLF is currently focused on select projects in certain micro markets.

As a part of strategic objectives, in 2007, DLF through its wholly-owned subsidiary, DLF Home Developers had entered into joint venture agreements with Ridgewood Holdings for development of seven residential projects in the cities of Bangalore, Chennai, Kochi and Indore.

DLFs consolidated net profit fell 22.9% to Rs 132.39 crore on 19.5% growth in net sales to Rs 2335.56 crore in Q4 March 2016 over Q4 March 2015.

DLFs primary business is development of residential, commercial and retail properties.

Powered by Capital Market - Live News

JBM Auto surges as JV to manufacture Indias first electric bus
Jul 20,2016

The announcement was made after market hours yesterday, 19 July 2016.

Meanwhile, the S&P BSE Sensex was up 73.36 points or 0.26% at 27,860.98.

On BSE, so far 16,000 shares were traded in the counter as against average daily volume of 3,361 shares in the past one quarter. The stock hit a high of Rs 140 and a low of Rs 135 so far during the day. The stock had hit a 52-week high of Rs 216 on 11 December 2015. The stock had hit a 52-week low of Rs 101 on 12 Febraury 2016. The stock had underperformed the market over the past one month till 19 July 2016, advancing 0.42% compared with Sensexs 4.36% rise. The scrip had also underperformed the market in past one quarter, sliding 8.97% as against Sensexs 7.64% rise.

The small-cap company has equity capital of Rs 20.40 crore. Face value per share is Rs 5.

Solaris Bus & Coach S.A. is a renowned European bus manufacturer. JBM Autos joint venture with Solaris JBM Solaris will invest Rs 300 crore towards engineering, design and development, manufacturing, supply chain development among other focus areas in this electric mobility project completely made in India.

On consolidated basis, JBM Autos net profit declined 45% to Rs 9.67 crore on 17.8% growth in net sales to Rs 385.38 crore in Q4 March 2016 over Q4 March 2015.

JBM Auto is the flagship company of JBM Group. The company is the leading manufacturer of auto components and buses in India.

Powered by Capital Market - Live News

Glenmark Pharma gains after receiving final approval from USFDA for a drug
Jul 20,2016

The announcement was made during market hours today, 20 July 2016.

Meanwhile, the BSE Sensex was up 63.44 points, or 0.23%, to 27,851.06.

On BSE, so far 16,973 shares were traded in the counter, compared with an average volume of 43,738 shares in the past one quarter. The stock hit a high of Rs 856.50 and a low of Rs 846.40 so far during the day. The stock hit a record high of Rs 1,261.95 on 21 August 2015. The stock hit a 52-week low of Rs 671.50 on 12 February 2016. The stock had outperformed the market over the past one month till 19 July 2016, gaining 10.01% compared with 4.36% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, rising 5.45% as against Sensexs 7.64% rise.

The large-cap company has an equity capital of Rs 28.22 crore. Face value per share is Re 1.

Glenmark Pharmaceuticals announced that it has been granted final approval by the United States Food & Drug Administration (USFDA) for Rosuvastatin Calcium Tablets, 5 mg (base), 10 mg (base), 20 mg (base), and 40 mg (base), the generic version of Crestor Tablets, 5 mg, 10 mg, 20 mg and 40 mg of IPR Pharmaceuticals, Inc.

According to IMS Health sales data for the twelve month period ended May 2016, Rosuvastatin Calcium Tablets, 5 mg (base), 10 mg (base), 20 mg (base), and 40 mg (base), market achieved annual sales in US of approximately $6.78 billion.

On a consolidated basis, Glenmark Pharmaceuticals net profit jumped 1516.31% to Rs 171.49 crore on 24% rise in net sales to Rs 2174.02 crore in Q4 March 2016 over Q4 March 2015.

Glenmark Pharmaceuticals is a research-driven, global, integrated pharmaceutical organization headquartered at Mumbai, India. Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of Inflammation (asthma/COPD, rheumatoid arthritis etc.) and pain (neuropathic pain and inflammatory pain).

Powered by Capital Market - Live News

Aurobindo Pharma in the pink of health
Jul 20,2016

The announcement was made during market hours today, 20 July 2016.

Meanwhile, the S&P BSE Sensex was up 71.42 points or 0.26% at 27,859.04.

On BE, so far 1 lakh shares were traded in the counter as against average daily volume of 1.19 lakh shares in the past one quarter. The stock hit a high of Rs 787.75 and a low of Rs 769.55 so far during the day. The stock had hit a record high of Rs 891.50 on 30 December 2015. The stock had hit a 52-week low of Rs 582 on 25 February 2016. The stock had outperformed the market over the past one month till 19 July 2016, advancing 4.5% compared with Sensexs 4.36% rise. The scrip had, however, underperformed the market in past one quarter, sliding 3.06% as against Sensexs 7.64% rise.

The large-cap company has equity capital of Rs 58.52 crore. Face value per share is Rs 1.

Aurobindo Pharma secured final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Rosuvastatin Calcium Tablets, 5 mg (base), 10 mg (base), 20 mg (base) and 40 mg (base). Aurobindo is eligible for 180 days of generic drug shared exclusivity. The product is launched in the US market.

The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) CRESTOR (rosuvastatin calcium) Tablets 5 mg, 10 mg, 20 mg and 40 mg of IPR Pharmaceuticals Inc.

Rosuvastatin Calcium Tablets is an antihyperlipidemic to prevent cardiovascular disease. The approved product has an estimated market size of $6.7 billion in the United States for the twelve months ended May 2016 according to IMS.

On consolidated basis, Aurobindo Pharmas net profit rose 39.4% to Rs 562.85 crore on 16.9% growth in net sales to Rs 3674.70 crore in Q4 March 2016 over Q4 March 2015.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The companys manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The companys robust product portfolio is spread over 7 major therapeutic/product areas encompassing antibiotics, anti-retrovirals, CVS, CNS, gastroenterologicals, anti-allergies and anti-diabetics, supported by an outstanding R&D set-up. The company is marketing these products globally, in over 150 countries.

Powered by Capital Market - Live News